substance dependence

临床试验

计划入组 600 人 · 首次发布于 2016 年 9 月 9 日

已完成

NCT00330239

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

计划入组 25 人 · 首次发布于 2006 年 5 月 26 日

已完成

NCT02461732

Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence

计划入组 60 人 · 首次发布于 2015 年 6 月 3 日

药物

查看全部 43 →

therapeutic agent (opiate dependence)

Small Molecule

Investigational

Sar9, Met (O2)11-Substance P

C₆₄H₁₀₀N₁₈O₁₅S

substance P antagonists (Adelaide University)

机构

查看全部 6 →

SUBSTANCE PTY LTD

Australia

Entheon Biomedical Corp

Canada

UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE

United States

资讯

查看全部 1154 →

去年

MediciNova Advances Dual-Pipeline Strategy with Novel Therapeutics for Neurological and Metabolic Disorders

3个月前

MediciNova Secures U.S. Patent Allowance for Ibudilast–Anti-PD-1 Combination in Glioblastoma

去年

临床试验

Substance Dependence Satisfaction With Care and Quality Of Life

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence

药物

therapeutic agent (opiate dependence)

Sar9, Met (O2)11-Substance P

substance P antagonists (Adelaide University)

机构

SUBSTANCE PTY LTD

Entheon Biomedical Corp

UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE

资讯

MediciNova Advances Dual-Pipeline Strategy with Novel Therapeutics for Neurological and Metabolic Disorders

MediciNova Secures U.S. Patent Allowance for Ibudilast–Anti-PD-1 Combination in Glioblastoma

MediciNova Secures $30 Million Standby Equity Agreement to Advance Neurological and Fibrotic Disease Programs